Fri, Apr 26, 2024
[Archive]
Volume 7, Issue 3 (Aug 2022)
JNFS 2022, 7(3): 379-387 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Musazadeh V, Dehghan P, Azadmard-Damirchi S. Effectiveness of Co-Administration of Camelina Oil and Caloric Restriction on Cardiometabolic Risk Factors, Liver Function and Mental Health in Patients with Non-Alcoholic Fatty Liver Disease: A Blinded Randomized Controlled Trial Protocol. JNFS 2022; 7 (3) :379-387
URL: http://jnfs.ssu.ac.ir/article-1-417-en.html
URL: http://jnfs.ssu.ac.ir/article-1-417-en.html
Nutrition Research Center, School of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract: (1426 Views)
Background: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease (CLD). Omega-3 fatty acids and antioxidants co-supplementation have been considered as an alternative treatment in NAFLD. This trial will evaluate camelina sativa oil (CSO) effects as a rich source of omega-3 fatty acids and antioxidants on cardiometabolic risk factors, metabolic endotoxemia, liver enzymes, hepatic steatosis, and mental health in NAFLD patients. Methods: Forty-six patients with NAFLD will be randomly assigned to either a CSO supplementation or placebo for 12 weeks. Both groups will receive a weight-loss diet too. Insulin resistance, oxidative stress, anti/inflammatory biomarkers, lipid profile, adiponectin, lipopolysaccharide (LPS), anthropometric indices, liver enzymes, hepatic steatosis, and cortisol will be assessed all patients at baseline and post-intervention. DASS and GHQ questionnaires will be completed for all patients at baseline and post-intervention. Results: The CSO is expected to reduce hepatic steatosis and improve cardiometabolic risk factors, liver function, and mental health compared to the placebo group after 12 weeks. Conclusion: The CSO as a phytopharmaceutical drug may improve cardiometabolic risk factors, metabolic endotoxemia, liver enzymes, hepatic steatosis, and mental health in patients with NAFLD.
Keywords: Fatty acids omega-3, Camelina oil, Oxidative stress, Inflammatory biomarkers, Non-alcoholic fatty liver disease
Type of article: orginal article |
Subject:
public specific
Received: 2021/05/28 | Published: 2022/08/19 | ePublished: 2022/08/19
Received: 2021/05/28 | Published: 2022/08/19 | ePublished: 2022/08/19
References
1. Abramovič H, Butinar B & Nikolič V 2007. Changes occurring in phenolic content, tocopherol composition and oxidative stability of Camelina sativa oil during storage. Food chemistry. 104 (3): 903-909.
2. Aebi H 1974. Catalase. In Methods of enzymatic analysis, pp. 673-684. Elsevier.
3. Araya J, et al. 2004. Increase in long-chain polyunsaturated fatty acid n− 6/n− 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clinical science. 106 (6): 635-643.
4. Budin JT, Breene WM & Putnam DH 1995. Some compositional properties of camelina (Camelina sativa L. Crantz) seeds and oils. Journal of the American oil chemists’ society. 72 (3): 309-315.
5. Chalasani N, et al. 2012. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 142 (7): 1592-1609.
6. de Mello VD, et al. 2019. The effect of different sources of fish and camelina sativa oil on immune cell and adipose tissue mRNA expression in subjects with abnormal fasting glucose metabolism: a randomized controlled trial. Nutrition & diabetes. 9 (1): 1-12.
7. Ergönül PG & Özbek ZA 2020. Cold pressed camelina (Camelina sativa L.) seed oil. In Cold pressed oils, pp. 255-266. Elsevier.
8. Erkkilä AT, et al. 2019. Camelina sativa oil, fatty fish, and lean fish do not markedly affect urinary prostanoids in subjects with impaired glucose metabolism. Lipids. 54 (8): 453-464.
9. Gutch M, Kumar S, Razi SM, Gupta KK & Gupta A 2015. Assessment of insulin sensitivity/resistance. Indian journal of endocrinology and metabolism. 19 (1): 160.
10. Hannah WN & Harrison SA 2016. Lifestyle and dietary interventions in the management of nonalcoholic fatty liver disease. Digestive diseases and sciences. 61 (5): 1365-1374.
11. Hardy T, Oakley F, Anstee QM & Day CP 2016. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annual review of pathology: mechanisms of disease. 11: 451-496.
12. Hu FB, Meigs JB, Li TY, Rifai N & Manson JE 2004. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 53 (3): 693-700.
13. Janczyk W, et al. 2013. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC pediatrics. 13 (1): 1-11.
14. McCarthy EM & Rinella ME 2012. The role of diet and nutrient composition in nonalcoholic fatty liver disease. Journal of the Academy of nutrition and dietetics. 112 (3): 401-409.
15. Mendes A, Reis A, Vasconcelos R, Guerra P & da Silva TL 2009. Crypthecodinium cohnii with emphasis on DHA production: a review. Journal of applied phycology. 21 (2): 199-214.
16. Musso G, Anty R & Petta S 2013. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients? Current pharmaceutical design. 19 (29): 5297-5313.
17. North American Association for the Study of Obesity 2000. National Heart, Lung, Blood Institute and NHLBI Obesity Education Initiative, the Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. .
18. Parker HM, et al. 2012. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of hepatology. 56 (4): 944-951.
19. Pereira EC, et al. 2008. Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus. Clinical biochemistry. 41 (18): 1454-1460.
20. Pocock SJ 2013. Clinical trials: a practical approach. John Wiley & Sons.
21. Raghukumar S 2008. Thraustochytrid marine protists: production of PUFAs and other emerging technologies. Marine biotechnology. 10 (6): 631-640.
22. Reccia I, et al. 2017. Non-alcoholic fatty liver disease: a sign of systemic disease. Metabolism. 72: 94-108.
23. Sahebi A, Asghari MJ & Salari RS 2005. Validation of depression anxiety and stress scale (DASS-21) for an Iranian population. Journal of developmental psychology. 1 (4).
24. Schwab US, et al. 2018. Camelina sativa oil, but not fatty fish or lean fish, improves serum lipid profile in subjects with impaired glucose metabolism—a randomized controlled trial. Molecular nutrition & food research. 62 (4): 1700503.
25. Thoma C, Day CP & Trenell MI 2012. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. Journal of hepatology. 56 (1): 255-266.
26. Utzschneider KM & Kahn SE 2006. The role of insulin resistance in nonalcoholic fatty liver disease. Journal of clinical endocrinology & metabolism. 91 (12): 4753-4761.
27. Vasheghani-Farahani A, et al. 2011. The Persian, last 7-day, long form of the International Physical Activity Questionnaire: translation and validation study. Asian journal of sports medicine. 2 (2): 106.
28. Yaghubi H, Karimi M & Omidi A 2012. Validity and Factor Structure f the General Health Questionnaire (GHQ-12) In University Students. International journal of behavioral sciences. 6 (2).
29. Younossi Z, et al. 2018. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature reviews gastroenterology & hepatology. 15 (1): 11-20.
30. Zubr J & Matthäus B 2002. Effects of growth conditions on fatty acids and tocopherols in Camelina sativa oil. Industrial crops and products. 15 (2): 155-162.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
